Navigation Links
John Theurer Cancer Center hosts New Frontiers in the Management of Solid and Liquid Tumors
Date:10/11/2011

HACKENSACK, N.J., (October 10, 2011) John Theurer Cancer Center at Hackensack University Medical Center, one of nation's top 50 best hospitals for cancer, will host the New Frontiers in the Management of Solid and Liquid Tumors on November 3-4 from 7:00am to 4:00pm. This complimentary Continuing Medical Education (CME) program will feature internationally recognized oncologists and hematologists who will provide the latest updates on state-of the-art treatment modalities including novel therapies and new prognostic models in hematological and solid tumors.

"The oncology treatment landscape is rapidly changing," Andre Goy, M.D., M.S., Chairman and Director and Chief of Lymphoma, John Theurer Cancer Center and the program Chair. "This program has been designed to help physicians gain additional insight into how translational research can be applied to the clinic for improved patient outcomes."

Key topics include emerging best practices and ongoing studies in hematological malignancies and solid tumors, the impact of novel therapies in the care of hematology-oncology and solid tumor patients, new modalities in imaging and its best use in cancer patients, biomarkers and new prognostic markers in lymphomas and leukemias, the impact of emerging molecular markers in solid tumors, and the shifting paradigms in the treatment of multiple myeloma. A 15-minute Q&A will follow all presentations.

"This is a great opportunity for physicians and healthcare professionals to hear about the newest research from leading oncology and hematology physicians," Stuart L. Goldberg, M.D., Chief, Leukemia, John Theurer Cancer Center and program Co-Chair. "We are fortunate to have some of the worlds' foremost experts in solid and liquid tumors present information that will guide the development of future therapies."

Featured Speakers and Topics for Thursday, November 3:

  • Volker Diehl, M.D., Professor, University of Cologne, Germany
    Customization: The Treatment of Hodgkin's Disease
  • Jean-Luc Harousseau, M.D., Professor of Hematology, Head, Dept. of Clinical Hematology, Director of the Cancer Center Rene Gauducheau, University of Nantes, France
    Impact of Novel Therapies in the Management of Multiple Myeloma
  • Richard Champlin, M.D., Chair, Dept. of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The Univ. of Texas MD Anderson Cancer Center
    Newest Modalities in Bone Marrow Transplantation
  • Thomas Habermann, M.D., Professor of Medicine, Division of Hematology, Mayo Clinic
    Treatment of Large-Cell Lymphoma
  • Susan O'Brien, M.D., Professor, Dept. of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center
    Newest Strategies in the Treatment of CML/CLL
  • Myron Czuczman, M.D., Professor Chief, Lymphoma/Myeloma Service, Dept. of Medicine Head, Lymphoma Translational Research Laboratory Dept. of Immunology Roswell Park Cancer Center
    Evolving Management of Follicular Lymphoma

Featured Speakers and Topics for Friday, November 4:

  • Shiladitya Sengupta, M.D., Assistant Professor of Medicine and Health Sciences and Technology, Harvard Medical School, Brigham & Women's Hospital
    Personalized Medicine Approaches in Oncology
  • Christoper Logothetis, M.D., Dept. Chair, Dept. of Genitourinary Medical Oncology, Division of Cancer Medicine, the Univ. of Texas MD Anderson Cancer Center
    Current Landscapes in the Management of Prostate Cancer
  • Christopher Azzoli, M.D., Assistant Member, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center
    Current Modalities in the Treatment of Lung Cancer
  • Axel Grothey, M.D., Professor of Oncology; Consultant, Medical Oncology, Mayo Clinic
    New Perspectives in GI Malignancies
  • Kevin R. Fox, M.D., Director, Rena Rowan Breast Center, Perelman Center for Advanced Medicine at Penn Medicine
    Newest Approach to Breast Cancer
  • Steven Horwitz, M.D., Assistant Attending, Lymphoma Service, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center
    Managing T-Cell Lymphoma

"We are committed to providing physicians and healthcare providers with the best educational programs to help clinicians manage today's most complicated cases in cancer," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services, John Theurer Cancer Center. "I would like to thank Dr. Goy for spearheading this important conference and the impressive panel of experts for presenting at the John Theurer Cancer Center."


'/>"/>

Contact: Amy Leahing
amy.leahing@zibbel.com
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients
2. John Theurer Cancer Center offers breakthrough radiation measurement technology
3. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
4. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
5. The John Theurer Cancer Center recognizes medical physics team for safety track record
6. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
7. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
8. John Theurer Cancer Center to present innovative research at 2 surgical meetings
9. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
10. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
11. Oncology basic research director at John Theurer Cancer Center continues transplantation research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: